Physician profile
Mitchell J Hebert
NPI 1861499154
$4,065.54
in general payments reported to CMS, 2019-2025
32 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $261 · 2021: $522 · 2022: $850 · 2023: $712 · 2024: $671 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $524.33 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $386.97 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $263.41 | 2021-2025 | Terlivaz, Acthar |
| Novartis Pharmaceuticals Corporation | $251.75 | 2020-2025 | |
| Fresenius USA Marketing, INC. | $239.81 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $238.90 | 2021-2025 | |
| Akebia Therapeutics INC | $195.64 | 2019-2024 | Auryxia, Vafseo |
| Horizon Therapeutics Plc | $174.43 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $169.62 | 2022-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $168.49 | 2022-2025 | Tarpeyo |
| Amgen INC. | $140.59 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Alexion Pharmaceuticals, INC. | $139.59 | 2019-2025 | Ultomiris |
| Novo Nordisk INC | $133.84 | 2024-2025 | Rivfloza, Wegovy, Rybelsus |
| Vifor Pharma, INC. | $133.21 | 2019-2023 | Veltassa, Korsuva |
| Baxter Healthcare | $120.22 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $87.83 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $85.04 | 2020-2024 | Injectafer |
| Opko Pharmaceuticals, LLC | $65.47 | 2022-2025 | Rayaldee |
| Ultragenyx Pharmaceutical INC. | $61.74 | 2021-2024 | Crysvita |
| Abiomed | $60.22 | 2020 | |
| Ardelyx, INC. | $57.53 | 2024-2025 | Ibsrela |
| Pharmacosmos Therapeutics INC. | $57.02 | 2021 | |
| Ani Pharmaceuticals, INC. | $49.57 | 2022-2025 | Purified Cortrophin Gel |
| Amag Pharmaceuticals, INC. | $40.16 | 2019-2021 | |
| Glaxosmithkline, LLC. | $39.56 | 2020-2023 | Jesduvroq |
| Travere Therapeutics, INC. | $35.32 | 2023-2024 | |
| Scpharmaceuticals INC. | $35.05 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.66 | 2023-2025 | Jynarque |
| Genzyme Corporation | $25.02 | 2023 | |
| Cormedix INC. | $20.41 | 2024 | Defencath |
| Xeris Pharmaceuticals, INC. | $15.59 | 2021 | |
| Apellis Pharmaceuticals, INC. | $14.55 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.